Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RebiQoL: Impact of MinSupport Plus on HRQoL in RRMS
NCT01791244Phase 4Completed
- Sponsor
- Merck KGaA
- Start
- Feb 2013
- Primary completion
- Feb 2016
- Modality
- Cytokines & Interferons
- Countries
- 2
01
Overview
A Phase 4 trial of interferon beta-1a in relapsing-remitting multiple sclerosis (RRMS), sponsored by Merck KGaA. Started Feb 2013; status: completed.
02
Drugs
interferon beta-1a
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT01791244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01791244.